Hemoglobin glutamer 250 bovine - HbO2 Therapeutics
Alternative Names: Bovine haemoglobin - HbO2 Therapeutics; Bovine hemoglobin; HBOC-201; Hemoglobin glutamer-250 (bovine) - HbO2 Therapeutics; Hemoglobin glutamer-250 - HbO2 Therapeutics; Hemoglobin glutamer-250 bovine - HbO2 Therapeutics; HemopureLatest Information Update: 09 Apr 2021
At a glance
- Originator Biopure Corporation
- Developer HbO2 Therapeutics
- Class Haemoglobins
- Mechanism of Action Haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
- No development reported Ischaemia; Shock
Most Recent Events
- 09 Apr 2021 Hemoglobin glutamer 250 bovine is still awaiting regulatory approval for Anaemia in USA
- 09 Apr 2021 No development reported - Phase-II for Ischaemia in Europe (IV)
- 09 Apr 2021 No development reported - Phase-II for Ischaemia in South Africa (IV)